3Q25 Financial Results Forward-Looking Statements; Non-GAAP Information This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2025 full-year guidance), our strategic roadmap and the steps thereof, our antic ...

Financial Performance Highlights - Bausch + Lomb reported Q2 2025 revenue of $1278 million, a 5% increase compared to $1216 million in Q2 2024[23] - Constant currency revenue growth was 3% in Q2 2025, and 6% excluding the impact of the enVista recall[12, 23] - Vision Care segment led growth with a 6% constant currency revenue increase in Q2 2025[23] - Adjusted EBITDA (excluding Acquired IPR&D) was $192 million, with an adjusted EBITDA margin of 150%[33] - Adjusted net income attributable to Bausch + Lomb was $25 million, or $007 per share[33] Segment Performance - Vision Care revenue increased by 8% to $753 million in Q2 2025[33] - Surgical revenue increased by 3% to $216 million in Q2 2025[33] - Pharmaceuticals revenue remained relatively flat at $309 million in Q2 2025[33] Future Outlook - Bausch + Lomb raised its FY25 revenue guidance to $505 billion - $515 billion[39] - The company anticipates constant currency revenue growth of approximately 5-7% for FY25[39]